Home › Scleroderma › Arizona
Pag-aaral pangklinika para sa Scleroderma sa Arizona
6 pag-aaral para sa Scleroderma ang naghahanap ng mga kalahok sa mga site sa Arizona.
Mga Lungsod sa Arizona
Opisyal na teksto ng pag-aaral (English)
A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis
- Arizona Arthritis and Rheumatology Associates, Phoenix
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 24, 2026 · NCT06655155A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis
- Banner - University Medicine Rheumatology Clinic, Phoenix
- Arizona Arthritis and Rheumatology Associates - Paradise Valley, Scottsdale
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 17, 2026 · NCT07497087A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
- Mayo Clinic, Phoenix
Nagre-recruitPhase 1
Edad 18 hanggang 74 · Lahat ng kasarian · Na-update Set 10, 2026 · NCT07085104A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
- GSK Investigational Site, Scottsdale
- GSK Investigational Site, Scottsdale
- GSK Investigational Site, Tucson
Nagre-recruitPhase 2/3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 8, 2026 · NCT05878717AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
- Artiva Investigational Site Phoenix, Phoenix
- Artiva Investigational Site Tucson, Tucson
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 31, 2026 · NCT06991114A Study of AZD0120 in Autoimmune Diseases
- Research Site, Tucson
Nagre-recruitPhase 1
Edad 18 hanggang 75 · Lahat ng kasarian · Na-update Hul 28, 2026 · NCT07295847Mula sa ClinicalTrials.gov, na-kuha noong Set 30, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.